Prince Edward Island announced implementation of a biosimilar switching policy consistent with ten other provinces in Canada. From 12 October 2023, patients covered under PEI Pharmacare program will begin switching biosimilars. Pharmacare beneficiaries will have until 30 June 2024 to work with healthcare providers to switch to a biosimilar. Patients currently using Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade® or Rituxan® will be transitioned to a biosimilar version by 30 June 2024 to maintain their coverage.
We reported on previous Canadian announcements of Biosimilar switching initiatives, including Newfoundland and Labrador, Yukon, Ontario, British Columbia, Alberta, New Brunswick, Quebec, Northwest Territories, Nova Scotia and Saskatchewan.